Gave ๐ฃ๏ธ to @DellMedVascular conference on empiric antibiotics in DFIs.
NEED โฌ๏ธ data in this space for antibiotic stewardship! Love to see it: https://t.co/3VGDHfqXCI
Also, MUST READ @Cortes_Penfield on team effort! โ https://t.co/0sLYJnr8XK #IDtwitter#SIDP
I hope we ๐ beta-lactams positioned more favorably for treatment of pyelo (including completion of outpatient ๐ therapy) in the next round of UTI guidelines!
As a bonus, ~20% of beta-lactams were cephalexin/cefadroxil. 1st gen cephs for the win! ๐
Happy Friday & Pre-Holiday Weekend! ๐ฅณ
Congrats to past @SetonPharmRes PGY2 ID #PharmRes@e_weissgerber and @Mike_McAl for your recent pubs! Y'all make us look good! Persistent pays off!
https://t.co/ZA3MoZ9fXe
https://t.co/cicvzcQhsN
Congratulations to our incomparable, amazing, and brilliant group of 2021/2022 #PharmRes! We are all so PROUD of what you have accomplished this year!
The future is BRIGHT for this crew! ๐๐ฅณ๐
Thank you @SIDPharm for this cool opportunity and a chance to ride the coat tails of our amazing PGY2 ID Resident @kell_siella one last time before she finishes our @SetonPharmRes program!
What is a safe and effective valganciclovir dose in HD SOT patients? @kell_siella and @stellarelement discuss valganciclovir dosing for CMV prophylaxis in our latest SIDP Journal Club Series release (https://t.co/gTtPZxZWAq), worth 1.5h of ACPE/BCIDP credit! #TxPharm#IDTwitterโ
(7/7)
We hope our experience (which echoes that of many others faced w/ drug toxicities from Paxlovid over the last few months) raises awareness and informs future discussions by the #FDA prior to the next EUA release that may hold foreseeable harm.
#BetterTogether ๐ #IDTwitter
๐๐ฅ๐ฅ@OFIDJournal Supratherapeutic tacrolimus concentrations with Paxlovid "nirmatrelvir/ritonavir" in solid organ transplant recipients requiring hospitalization: A case series using rifampin for reversal #IDTwitter#MedEd#TwitteRx https://t.co/OUxe58ns2j
(6/n)
Now, more prescriptive guidance around these DDIs from state health depts, @NIHCOVIDTxGuide, @IDSAInfo, @covidDDIs, and other societies is moving the needle on improving patient safety ๐
Happy Friday!!
As I prepare for a panel discussion on PCN allergies and de-labeling, I learned, or re-learned, some interesting facts.
Here are five that may (or may not) be new to you:
1) Approximately 75% of PCN allergy labels are applied by the age of 3.
Our residents ROCKED their presentations on their research ๐ง๐ projects at Alcalde the past โ๐ปdays! Take a ๐ for yourself!
#PharmRes@TSHP_org@UTexasPharmacy
@justin_denholm@ABsteward@OFIDJournal Controls would be helpful. Definitely interested in what others are seeing for timing back to tac goals without intervention.